{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T17:54:31Z","timestamp":1770486871006,"version":"3.49.0"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100007911","name":"University of California, San Diego","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007911","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["EY 018589"],"award-info":[{"award-number":["EY 018589"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["EY020617"],"award-info":[{"award-number":["EY020617"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30EY022589"],"award-info":[{"award-number":["P30EY022589"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001818","name":"Research to Prevent Blindness","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001818","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"published-print":{"date-parts":[[2015,1]]},"DOI":"10.1016\/j.ejpb.2014.12.010","type":"journal-article","created":{"date-parts":[[2014,12,13]],"date-time":"2014-12-13T11:05:32Z","timestamp":1418468732000},"page":"271-279","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"special_numbering":"C","title":["Micelle formulation of hexadecyloxypropyl-cidofovir (HDP-CDV) as an intravitreal long-lasting delivery system"],"prefix":"10.1016","volume":"89","author":[{"given":"Feiyan","family":"Ma","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaihui","family":"Nan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"SuNa","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James R.","family":"Beadle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huiyuan","family":"Hou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William R.","family":"Freeman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karl Y.","family":"Hostetler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lingyun","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejpb.2014.12.010_b0005","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1053\/j.ajkd.2005.02.010","article-title":"Antiviral drug-induced nephrotoxicity","volume":"45","author":"Izzedine","year":"2005","journal-title":"Am. J. Kidney Diseases: Official J. Natl. Kidney Found."},{"key":"10.1016\/j.ejpb.2014.12.010_b0010","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.2146\/ajhp090424","article-title":"Drug interactions and toxicities associated with the antiviral management of cytomegalovirus infection","volume":"67","author":"Jacobsen","year":"2010","journal-title":"Am. J. Health Syst. Pharm."},{"key":"10.1016\/j.ejpb.2014.12.010_b0015","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1167\/iovs.12-11172","article-title":"Oxidized porous silicon particles covalently grafted with daunorubicin as a sustained intraocular drug delivery system","volume":"54","author":"Chhablani","year":"2013","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.ejpb.2014.12.010_b0020","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.jconrel.2014.01.003","article-title":"Tunable sustained intravitreal drug delivery system for daunorubicin using oxidized porous silicon","volume":"178","author":"Hou","year":"2014","journal-title":"J. Controlled Release"},{"key":"10.1016\/j.ejpb.2014.12.010_b0025","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1016\/S0142-9612(01)00284-8","article-title":"Ocular disposition and tolerance of ganciclovir-loaded albumin nanoparticles after intravitreal injection in rats","volume":"23","author":"Merodio","year":"2002","journal-title":"Biomaterials"},{"key":"10.1016\/j.ejpb.2014.12.010_b0030","doi-asserted-by":"crossref","first-page":"3485","DOI":"10.1016\/j.biomaterials.2012.01.030","article-title":"The movement of self-assembled amphiphilic polymeric nanoparticles in the vitreous and retina after intravitreal injection","volume":"33","author":"Koo","year":"2012","journal-title":"Biomaterials"},{"key":"10.1016\/j.ejpb.2014.12.010_b0035","doi-asserted-by":"crossref","first-page":"4138","DOI":"10.1167\/iovs.04-0064","article-title":"Characterization of a novel intraocular drug-delivery system using crystalline lipid antiviral prodrugs of ganciclovir and cyclic cidofovir","volume":"45","author":"Cheng","year":"2004","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.ejpb.2014.12.010_b0040","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1167\/iovs.09-3672","article-title":"Intravitreal crystalline drug delivery for intraocular proliferation diseases","volume":"51","author":"Cheng","year":"2010","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.ejpb.2014.12.010_b0045","doi-asserted-by":"crossref","first-page":"98","DOI":"10.7326\/0003-4819-125-2-199607150-00003","article-title":"Treatment of cytomegalovirus retinitis with intravitreous cidofovir in patients with AIDS. A preliminary report","volume":"125","author":"Rahhal","year":"1996","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.ejpb.2014.12.010_b0050","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/S0161-6420(97)30188-2","article-title":"Low-dose intravitreal cidofovir (HPMPC) therapy of cytomegalovirus retinitis in patients with acquired immune deficiency syndrome","volume":"104","author":"Taskintuna","year":"1997","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ejpb.2014.12.010_b0055","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1177\/112067210601600120","article-title":"Intravitreal triamcinolone acetonide as primary treatment for diffuse diabetic macular edema: a prospective noncomparative interventional case series","volume":"16","author":"Nicolo","year":"2006","journal-title":"Eur. J. Ophthalmol."},{"key":"10.1016\/j.ejpb.2014.12.010_b0060","first-page":"1523","article-title":"Intravitreal toxicology and duration of efficacy of a novel antiviral lipid prodrug of ganciclovir in liposome formulation","volume":"41","author":"Cheng","year":"2000","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.ejpb.2014.12.010_b0065","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1089\/108076801750295326","article-title":"Evaluation of intraocular pharmacokinetics and toxicity of prinomastat (AG3340) in the rabbit","volume":"17","author":"Cheng","year":"2001","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"10.1016\/j.ejpb.2014.12.010_b0070","doi-asserted-by":"crossref","first-page":"742","DOI":"10.3109\/02713683.2010.486519","article-title":"Intraocular properties of a repository urokinase receptor antagonist a36 Peptide in rabbits","volume":"35","author":"Falkenstein","year":"2010","journal-title":"Curr. Eye Res."},{"key":"10.1016\/j.ejpb.2014.12.010_b0075","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1136\/bjo.87.8.972","article-title":"Pseudo-endophthalmitis after intravitreal injection of triamcinolone","volume":"87","author":"Sutter","year":"2003","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.ejpb.2014.12.010_b0080","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1128\/AAC.46.8.2381-2386.2002","article-title":"Alkoxyalkyl esters of cidofovir and cyclic cidofovir exhibit multiple-log enhancement of antiviral activity against cytomegalovirus and herpesvirus replication in vitro","volume":"46","author":"Beadle","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejpb.2014.12.010_b0085","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1158\/1535-7163.MCT-05-0200","article-title":"Enhanced antiproliferative effects of alkoxyalkyl esters of cidofovir in human cervical cancer cells in vitro","volume":"5","author":"Hostetler","year":"2006","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ejpb.2014.12.010_b0090","doi-asserted-by":"crossref","first-page":"9391","DOI":"10.1167\/iovs.11-8293","article-title":"Intraocular safety and pharmacokinetics of hexadecyloxypropyl-cidofovir (HDP-CDV) as a long-lasting intravitreal antiviral drug","volume":"52","author":"Wang","year":"2011","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.ejpb.2014.12.010_b0095","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1021\/ed070p254","article-title":"Determining the critical micelle concentration of aqueous surfactant solutions \u2013 using a novel colorimetric method","volume":"70","author":"Furton","year":"1993","journal-title":"J. Chem. Educ."},{"key":"10.1016\/j.ejpb.2014.12.010_b0100","first-page":"1907","article-title":"A novel cytarabine crystalline lipid prodrug: hexadecyloxypropyl cytarabine 3\u2032,5\u2032-cyclic monophosphate for proliferative vitreoretinopathy","volume":"18","author":"Kim","year":"2012","journal-title":"Mol. Vision"},{"key":"10.1016\/j.ejpb.2014.12.010_b0105","first-page":"515","article-title":"Treatment or prevention of herpes simplex virus retinitis with intravitreally injectable crystalline 1-O-hexadecylpropanediol-3-phospho-ganciclovir","volume":"43","author":"Cheng","year":"2002","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.ejpb.2014.12.010_b0110","first-page":"325","article-title":"Treatment of herpes retinitis in an animal model with a sustained delivery antiviral drug, liposomal 1-O-octadecyl-SN-glycerol-3-phosphonoformate","volume":"19","author":"Cheng","year":"1999","journal-title":"Retina"},{"key":"10.1016\/j.ejpb.2014.12.010_b0115","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1056\/NEJMoa1102673","article-title":"Ranibizumab and bevacizumab for neovascular age-related macular degeneration","volume":"364","author":"Group","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejpb.2014.12.010_b0120","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.ijpharm.2009.06.020","article-title":"Liposome coated with low molecular weight chitosan and its potential use in ocular drug delivery","volume":"379","author":"Li","year":"2009","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2014.12.010_b0125","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.jconrel.2008.12.018","article-title":"Polymeric nanoparticulate system: a potential approach for ocular drug delivery","volume":"136","author":"Nagarwal","year":"2009","journal-title":"J. Controlled Release"},{"key":"10.1016\/j.ejpb.2014.12.010_b0130","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.3109\/03639041003680826","article-title":"PLGA\u2013PEG\u2013PLGA hydrogel for ocular drug delivery of dexamethasone acetate","volume":"36","author":"Gao","year":"2010","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.ejpb.2014.12.010_b0135","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1177\/0192623307310955","article-title":"Safety evaluation of ocular drug delivery formulations: techniques and practical considerations","volume":"36","author":"Short","year":"2008","journal-title":"Toxicol. Pathol."},{"key":"10.1016\/j.ejpb.2014.12.010_b0140","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s11095-008-9745-6","article-title":"Investigating the movement of intravitreal human serum albumin nanoparticles in the vitreous and retina","volume":"26","author":"Kim","year":"2009","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2014.12.010_b0145","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1113\/jphysiol.1959.sp006151","article-title":"Chemistry and rate of turnover of the ocular fluids of the bush baby (Galago-Crassicaudatus-Agisymbanus)","volume":"145","author":"Davson","year":"1959","journal-title":"J. Physiol. \u2013 London"},{"key":"10.1016\/j.ejpb.2014.12.010_b0150","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1136\/bjo.68.3.145","article-title":"Routes of clearance of radioactive water from the rabbit vitreous","volume":"68","author":"Moseley","year":"1984","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.ejpb.2014.12.010_b0155","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0002-9394(14)74163-7","article-title":"Use of intravitreal ganciclovir (dihydroxy propoxymethyl guanine) for cytomegalovirus retinitis in a patient with AIDS","volume":"103","author":"Henry","year":"1987","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.ejpb.2014.12.010_b0160","doi-asserted-by":"crossref","first-page":"569","DOI":"10.3109\/02713689609000768","article-title":"Distribution and metabolism of intravitreal cidofovir and cyclic HPMPC in rabbits","volume":"15","author":"Cundy","year":"1996","journal-title":"Curr. Eye Res."},{"key":"10.1016\/j.ejpb.2014.12.010_b0165","first-page":"1557","article-title":"Lack of retinal toxicity of the anticytomegalovirus drug (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl) cytosine","volume":"33","author":"Dolnak","year":"1992","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.ejpb.2014.12.010_b0170","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1089\/jop.1998.14.147","article-title":"Intravitreal and plasma cidofovir concentrations after intravitreal and intravenous administration in AIDS patients with cytomegalovirus retinitis","volume":"14","author":"Taskintuna","year":"1998","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"10.1016\/j.ejpb.2014.12.010_b0175","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1089\/108076803321637690","article-title":"Ganciclovir release rates in vitreous from different formulations of 1-O-hexadecylpropanediol-3-phospho-ganciclovir","volume":"19","author":"Cheng","year":"2003","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"10.1016\/j.ejpb.2014.12.010_b0180","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1016\/j.ophtha.2010.03.031","article-title":"Course of cytomegalovirus retinitis in the era of highly active antiretroviral therapy: five-year outcomes","volume":"117","author":"Jabs","year":"2010","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ejpb.2014.12.010_b0185","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1056\/NEJM199803263381301","article-title":"Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV outpatient study investigators","volume":"338","author":"Palella","year":"1998","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejpb.2014.12.010_b0190","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/S0161-6420(96)30548-4","article-title":"New developments in the treatment of CMV retinitis","volume":"103","author":"Freeman","year":"1996","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ejpb.2014.12.010_b0195","first-page":"215","article-title":"Cidofovir, a new addition to the available therapies against cytomegalovirus","volume":"vol. 21","author":"De Cian","year":"1998"}],"container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641114003658?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641114003658?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T16:32:51Z","timestamp":1760545971000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939641114003658"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1]]},"references-count":39,"alternative-id":["S0939641114003658"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpb.2014.12.010","relation":{},"ISSN":["0939-6411"],"issn-type":[{"value":"0939-6411","type":"print"}],"subject":[],"published":{"date-parts":[[2015,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Micelle formulation of hexadecyloxypropyl-cidofovir (HDP-CDV) as an intravitreal long-lasting delivery system","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutics and Biopharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpb.2014.12.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}